ACLA News

  • Statement on CMS Proposed Physician Fee Schedule Rule

    July 09, 2013
    WASHINGTON, DC – The American Clinical Laboratory Association (ACLA) issued the following statement on the proposed rule published today in the Federal Register by the Centers for Medicare and Medicaid Services (CMS), “Medicare Program: Revisions to Payment Policies under the Physician Fee Schedule, Clinical Laboratory Fee Schedule & Other Revisions for Part B for CY 2014” (the “Proposed Rule”): ACLA is deeply concerned withContinue Reading »...
  • Statement on CMS Proposed Physician Fee Schedule Rule

    July 09, 2013
    WASHINGTON, DC – The American Clinical Laboratory Association (ACLA) issued the following statement on the proposed rule published today in the Federal Register by the Centers for Medicare and Medicaid Services (CMS), “Medicare Program: Revisions to Payment Policies under the Physician Fee Schedule, Clinical Laboratory Fee Schedule & Other Revisions for Part B for CY 2014” (the “Proposed Rule”): ACLA is deeply concerned withContinue Reading »...
  • ACLA Submits Comments on Gapfill Pricing for Molecular Pathology Services

    July 02, 2013
    (WASHINGTON, D.C.) The American Clinical Laboratory Association (ACLA) submitted comments today to the Centers for Medicare & Medicaid Services’ (CMS) regarding the agency’s 2013 gapfill pricing under the Clinical Laboratory Fee Schedule (CLFS) for molecular pathology services. For 2013, CMS decided to use the gapfilling methodology to establish payment rates for more than 100 new Tier I and Tier II molecular pathology test codesContinue Reading »...
  • Statement Regarding OIG Report on Medicare Spending on Clinical Lab Services

    June 12, 2013
    Washington, D.C. (June 12, 2013) – The Department of Health and Human Services (HHS) Office of Inspector General (OIG) yesterday released a report, “Comparing Lab Test Payment Rates: Medicare Could Achieve Substantial Savings.” The report examined 20 of the 1100 laboratory test codes (HCPCS) and concluded that Medicare paid “more than other insurers” for these codes. The American Clinical Laboratory Association (ACLA) saw theContinue Reading »...
  • Clinical Labs Industry Files Petition Against Potential FDA Regulation of Laboratory Developed Tests

    June 04, 2013
    Washington, D.C. — The American Clinical Laboratory Association (ACLA) filed today a citizen petition under the Federal Food, Drug, and Cosmetic Act (FDCA) challenging Food and Drug Administration (FDA) authority to regulate laboratory developed tests (LDTs) in response to statements that the agency intends to regulate LDTs as “devices” under the FDCA. As detailed in ACLA’s petition, LDTs are in vitro assays that clinicalContinue Reading »...
  • ACLA Opposes Further Cuts To Clinical Laboratories In President’s 2014 Budget – Proposal Would Cut Lab Reimbursement By An Additional 14% Over Ten Years

    April 10, 2013
    (Washington, DC) – The American Clinical Laboratory Association (ACLA) strongly opposes a proposal in the President’s 2014 budget that would reduce reimbursement for clinical laboratory services in Medicare by an additional $9.460 billion over ten years, a cut of at least 14% over ten years. This proposal, on top of the cuts already scheduled under current law, would bring total cuts to the ClinicalContinue Reading »...
  • ACLA Applauds Enactment of Bill Increasing Flexibility of Regulations that Threaten Access to Clinical Lab Tests

    December 04, 2012
    For Release: December 4, 2012 Contact: Jason DuBois, 202-637-9466 ACLA Applauds Enactment of Bill Increasing Flexibility of Regulations that Threaten Access to Clinical Lab Tests WASHINGTON, DC — The American Clinical Laboratory Association (ACLA) today applauded President Barack Obama for signing into law the Taking Essential Steps for Testing Act (TEST Act), introduced in the House by Rep. Michael Grimm (R-NY) and in theContinue Reading »...
  • ACLA Lauds Senate Approval of Bill Increasing Flexibility of Regulations that Threaten Access to Clinical Lab Tests

    November 15, 2012
    For Release: November 15, 2012 Contact: Jason Dubois, 202-637-9466 ACLA Lauds Senate Approval of Bill Increasing Flexibility of Regulations that Threaten Access to Clinical Lab Tests WASHINGTON, DC — The American Clinical Laboratory Association (ACLA) today applauded the U.S. Senate for yesterday’s passage of the Taking Essential Steps for Testing Act (TEST Act), introduced in the House by Rep. Michael Grimm (R-NY). The HouseContinue Reading »...
  • ACLA Applauds CMS’ Decision on Medicare Payment for Molecular Diagnostic Laboratory Tests; Has Serious Concerns About Drastic Cuts to Pathology Services

    November 02, 2012
    November 2, 2012 For Immediate Release Contact: Alan Mertz, 202-637-9466 ACLA Applauds CMS’ Decision on Medicare Payment for Molecular Diagnostic Laboratory Tests; Has Serious Concerns About Drastic Cuts to Pathology Services Washington, DC. The American Clinical Laboratory Association (ACLA) applauds the release yesterday of a final decision by the Centers for Medicare and Medicaid Services (CMS) regarding Medicare payment for molecular diagnostic tests performedContinue Reading »...
  • Controlling Chronic Kidney Disease Saves Lives and Money

    October 11, 2012
    Contact: Scott McGoohan American Clinical Laboratory Association Tel: 202.637.9466 Oct. 11, 2012 Controlling Chronic Kidney Disease Saves Lives and Money Low-Cost Lab Tests Help Slow a Disease Costing $60 Billion Annually WASHINGTON – There’s little debate about one health care issue: Taking steps to control chronic kidney disease will save lives and money. That’s especially true if you have diabetes or high blood pressure,Continue Reading »...
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15